Clinical Research Directory
Browse clinical research sites, groups, and studies.
Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)
Sponsor: Harbin Medical University
Summary
This study is a prospective, multicenter, open-label, non-inferiority, randomized controlled trial. A total of 2,000 patients with STEMI (\<24 hours or 7-14 days) or NSTEMI will be recruited from at least 20 centers in China. Eligible patients must have residual DS \< 70% at the culprit lesion assessed by QCA, with optional thrombus aspiration, and TIMI flow of grade 3. Patients will be randomly assigned in a 1:1 ratio to the experimental group or the control group. The planned enrollment period is 36 months, and all patients will be followed up for at least 12 months after randomization, with continued follow-up until the end of the study. The primary outcome is the first occurrence of TLF after randomization, defined as the composite of cardiovascular death, target vessel myocardial infarction, ischemia-driven target lesion revascularization. The study aims to verify whether guideline-recommended standard medical therapy is non-inferior to DES implantation combined with guideline-recommended standard medical therapy in AMI patients with non-severe coronary artery stenosis. A total of 120 participants (60 in the experimental group and 60 in the control group) enrolled at the Second Affiliated Hospital of Harbin Medical University were included in the functional substudy. Using Abbott Pressure Wire™X pressure wire test functional indicators, and explore the incidence of coronary microvascular dysfunction (CMD) as assessed by the index of microcirculatory resistance (IMR) in two groups, and its impact on the rate of the composite endpoint of all-cause death and heart failure readmission occurring for the first time within 12 months.
Official title: Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis: a Prospective, Multicenter, Open-label, Non-inferiority, Randomised Controlled Trial(EROSION IV)
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
2000
Start Date
2026-07-13
Completion Date
2030-12
Last Updated
2026-07-16
Healthy Volunteers
No
Conditions
Interventions
Guideline-recommended standard medical therapy alone
Dual antiplatelet therapy, anticoagulation, thrombolysis, lipid-lowering, and other guideline recommended drugs related to myocardial infarction
DES implantation plus guideline-recommended standard medical therapy
DES implantation plus dual antiplatelet therapy, anticoagulation, thrombolysis, lipid-lowering, and other guideline recommended drugs related to myocardial infarction.
Locations (48)
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Beijing Luhe Hospital Affiliated to Capital Medical University
Beijing, China
Fuwai Hospital, Chinese Academy of Medical Sciences
Beijing, China
Cangzhou Central Hospital
Cangzhou, China
Chengde Medical College Affiliated Hospital
Chengde, China
Sichuan Provincial People's Hospital
Chengdu, China
The Central Hospital Affiliated to Dalian University of Technology
Dalian, China
The First Affiliated Hospital of Dalian Medical University
Dalian, China
The Second Affiliated Hospital of Dalian Medical University
Dalian, China
Daqing Oilfield General Hospital
Daqing, China
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, China
The Third Xiangya Hospital of Central South University
Hunan, China
Central Hospital of Jiamusi City
Jiamusi, China
The First Affiliated Hospital of Jiamusi University
Jiamusi, China
China-Japan Union Hospital of Jilin University
Jilin City, China
Jilin Central Hospital
Jilin City, China
The First Hospital of Jilin University
Jilin City, China
Shandong Provincial Hospital
Jinan, China
The Affiliated Hospital of Jining Medical University
Jining, China
Lanzhou University First Hospital
Lanzhou, China
Linyi People's Hospital
Linyi, China
Mudanjiang Cardiovascular Hospital
Mudanjiang, China
The First Affiliated Hospital of Nanyang Medical College
Nanyang, China
The Affiliated Hospital of Qingdao University
Qingdao, China
Qiqihar First Hospital
Qiqihar, China
The Second Affiliated Hospital of Qiqihar Medical University
Qiqihar, China
The Third Affiliated Hospital of Qiqihar Medical University
Qiqihar, China
Liaoning Provincial People's Hospital
Shenyang, China
Shengjing Hospital of China Medical University
Shenyang, China
The Fourth Affiliated Hospital of China Medical University
Shenyang, China
The Second Hospital of Hebei Medical University
Shijia Zhuang, China
Hebei Provincial People's Hospital
Shijiazhuang, China
Suihua First Hospital
Suihua, China
General Hospital of Taiyuan Iron and Steel (Group) Co.
Taiyuan, China
Shanxi Provincial Cardiovascular Hospital
Taiyuan, China
General Hospital of Tianjin Medical University
Tianjin, China
TEDA International Cardiovascular Hospital
Tianjin, China
Tianjin Chest Hospital
Tianjin, China
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Wuhan Asia Heart Hospital
Wuhan, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
People's Hospital of Xinjiang Uygur Autonomous Region
Xinjiang, China
The First Affiliated Hospital of Xinjiang Medical University
Xinjiang, China
Yantai Yuhuangding Hospital
Yantai, China
Fuwai Huazhong Cardiovascular Hospital
Zhengzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Zunyi Medical University Affiliated Hospital
Zunyi, China